The Mikaela Naylon Give Kids a Chance Act aims to enhance the development and availability of treatments for pediatric cancers by improving research into the use of existing and new drugs, particularly molecularly targeted therapies. The Act introduces requirements for drug manufacturers to conduct pediatric studies when seeking approval for cancer treatments, ensuring that these studies yield meaningful data on dosing, safety, and effectiveness for children.